A Multicenter, Double-Blind, Randomized, 12-Month, Placebo-Controlled Study to Evaluate the Lipid-Lowering Effect, Safety and Tolerability of AVE5530 25 mg/Day and 50mg/Day When Added to Ongoing Stable Statin Therapy (HMG-CoA Reductase Inhibitors) in Patients With Primary Hypercholesterolaemia.
Phase of Trial: Phase III
Latest Information Update: 17 May 2016
At a glance
- Drugs Canosimibe (Primary)
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 28 Apr 2012 Additional trial location (Portugal) identified as reported by EudraCT.
- 13 Nov 2009 Actual patient number (1015) added as reported by ClinicalTrials.gov.